226 related articles for article (PubMed ID: 31344647)
21. Similarity demonstrated between isolated charge variants of MB02, a biosimilar of bevacizumab, and Avastin® following extended physicochemical and functional characterization.
Ruppen I; Beydon ME; Solís C; Sacristán D; Vandenheede I; Ortiz A; Sandra K; Adhikary L
Biologicals; 2022 Jun; 77():1-15. PubMed ID: 35667958
[TBL] [Abstract][Full Text] [Related]
22. Forced Degradation of Monoclonal Antibodies After Compounding: Impact on Routine Hospital Quality Control.
Jaccoulet E; Daniel T; Prognon P; Caudron E
J Pharm Sci; 2019 Oct; 108(10):3252-3261. PubMed ID: 31201907
[TBL] [Abstract][Full Text] [Related]
23. Assessment of structural and functional similarity of biosimilar products: Bevacizumab as a case study.
Bhattacharya S; Rathore AS
J Chromatogr B Analyt Technol Biomed Life Sci; 2023 Sep; 1229():123896. PubMed ID: 37776677
[TBL] [Abstract][Full Text] [Related]
24. Comparability of biosimilar filgrastim with originator filgrastim: protein characterization, pharmacodynamics, and pharmacokinetics.
Sörgel F; Schwebig A; Holzmann J; Prasch S; Singh P; Kinzig M
BioDrugs; 2015 Apr; 29(2):123-31. PubMed ID: 25837839
[TBL] [Abstract][Full Text] [Related]
25. Development of the Drug Product Formulation of the Bevacizumab Biosimilar PF-06439535 (Bevacizumab-bvzr).
Ingram RL; Weiser SE
Drugs R D; 2023 Mar; 23(1):55-64. PubMed ID: 36811761
[TBL] [Abstract][Full Text] [Related]
26. Analytical Similarity of a Proposed Biosimilar BVZ-BC to Bevacizumab.
Yu C; Zhang F; Xu G; Wu G; Wang W; Liu C; Fu Z; Li M; Guo S; Yu X; Wang L
Anal Chem; 2020 Feb; 92(4):3161-3170. PubMed ID: 31983199
[TBL] [Abstract][Full Text] [Related]
27. Recommendations for the Development and Validation of Immunogenicity Assays in Support of Biosimilar Programs.
Civoli F; Kasinath A; Cai XY; Wadhwa M; Exley A; Oldfield P; Alvandkouhi S; Schaffar G; Chappell J; Bowsher R; Devanarayan V; Marini J; Rebarchak S; Anderson M; Koppenburg V; Lester T
AAPS J; 2019 Dec; 22(1):7. PubMed ID: 31792633
[TBL] [Abstract][Full Text] [Related]
28. Comprehensive Physicochemical and Biological Characterization of the Proposed Biosimilar Darbepoetin Alfa, LBDE, and Its Originator Darbepoetin Alfa, NESP
Jeong YR; Jeong RU; Son JH; Kwon JC; Jung S; Song MA; Hwang JA; Lee GM
BioDrugs; 2018 Apr; 32(2):153-168. PubMed ID: 29556960
[TBL] [Abstract][Full Text] [Related]
29. Aggregation of biopharmaceuticals in human plasma and human serum: implications for drug research and development.
Arvinte T; Palais C; Green-Trexler E; Gregory S; Mach H; Narasimhan C; Shameem M
MAbs; 2013; 5(3):491-500. PubMed ID: 23571158
[TBL] [Abstract][Full Text] [Related]
30. Biosimilarity under stress: A forced degradation study of Remicade® and Remsima™.
Pisupati K; Benet A; Tian Y; Okbazghi S; Kang J; Ford M; Saveliev S; Sen KI; Carlson E; Tolbert TJ; Ruotolo BT; Schwendeman SP; Schwendeman A
MAbs; 2017 Oct; 9(7):1197-1209. PubMed ID: 28787231
[TBL] [Abstract][Full Text] [Related]
31. Comparison of originator and biosimilar monoclonal antibodies using HRMS, Fc affinity chromatography, and 2D-HPLC.
Reinders LMH; Klassen MD; Teutenberg T; Jaeger M; Schmidt TC
Anal Bioanal Chem; 2022 Sep; 414(23):6761-6769. PubMed ID: 35895102
[TBL] [Abstract][Full Text] [Related]
32. Analytical similarity assessment of MYL-1402O to reference Bevacizumab.
Goyal P; Vats B; Subbarao M; Honnappa CG; Kabadi P; Rohil S; Bera A; Mehta GR; Pai H; Adhikari L; Tagore R; Sharma S; Venkatachala R; Nair P; Annegowda S; Sahu A; Trivedi S; Shastri N; Gokhale Y; Thomas R; Thakur A; Mohan D; Rao K U; Melarkode R; Ullanat R
Expert Opin Biol Ther; 2022 Feb; 22(2):271-298. PubMed ID: 34465264
[TBL] [Abstract][Full Text] [Related]
33. Assessing Analytical Similarity of Proposed Amgen Biosimilar ABP 501 to Adalimumab.
Liu J; Eris T; Li C; Cao S; Kuhns S
BioDrugs; 2016 Aug; 30(4):321-38. PubMed ID: 27461107
[TBL] [Abstract][Full Text] [Related]
34. Impact of Buffer, Protein Concentration and Sucrose Addition on the Aggregation and Particle Formation during Freezing and Thawing.
Hauptmann A; Podgoršek K; Kuzman D; Srčič S; Hoelzl G; Loerting T
Pharm Res; 2018 Mar; 35(5):101. PubMed ID: 29556730
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of analytical similarity between trastuzumab biosimilar CT-P6 and reference product using statistical analyses.
Lee J; Kang HA; Bae JS; Kim KD; Lee KH; Lim KJ; Choo MJ; Chang SJ
MAbs; 2018; 10(4):547-571. PubMed ID: 29482416
[TBL] [Abstract][Full Text] [Related]
36. Impact of Excipient Extraction and Buffer Exchange on Recombinant Monoclonal Antibody Stability.
Sarin D; Krishna K; Nejadnik MR; Suryanarayanan R; Rathore AS
Mol Pharm; 2024 Apr; 21(4):1872-1883. PubMed ID: 38422397
[TBL] [Abstract][Full Text] [Related]
37. Silicone oil microdroplets and protein aggregates in repackaged bevacizumab and ranibizumab: effects of long-term storage and product mishandling.
Liu L; Ammar DA; Ross LA; Mandava N; Kahook MY; Carpenter JF
Invest Ophthalmol Vis Sci; 2011 Feb; 52(2):1023-34. PubMed ID: 21051703
[TBL] [Abstract][Full Text] [Related]
38. Physicochemical and Biological Characterization of the Proposed Biosimilar Tocilizumab.
Miao S; Fan L; Zhao L; Ding D; Liu X; Wang H; Tan WS
Biomed Res Int; 2017; 2017():4926168. PubMed ID: 28349061
[TBL] [Abstract][Full Text] [Related]
39. Analytical comparability study of anti-CD20 monoclonal antibodies rituximab and obinutuzumab using a stability-indicating orthogonal testing protocol: Effect of structural optimization and glycoengineering.
Trabik YA; Moenes EM; Al-Ghobashy MA; Nebsen M; Ayad MF
J Chromatogr B Analyt Technol Biomed Life Sci; 2020 Nov; 1159():122359. PubMed ID: 32920338
[TBL] [Abstract][Full Text] [Related]
40. Stability and Biosimilarity Assessment of Bevacizumab Monoclonal Antibody; Orthogonal Testing Protocol Coupled With Peptide Mapping-Principal Component Analysis.
Abdelghaffar SH; Hegazy MA; Eltanany BM
J AOAC Int; 2024 Jan; 107(1):177-188. PubMed ID: 37606972
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
